CD19 and neoplasm: In our in vitro experiments, we show that co-culture of T cells equipped with the CAR/CCR construct with CD19+ tumor cell lines with different CD80/86 expression patterns results in significantly lower IL-2 release after antigen-specific activation compared with T cells equipped with a 2nd Gen CAR construct (Tisagenlecleucel).